Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients—a description of the DAPACARD study
Background: Diabetes increases the risk for cardiovascular (CV) events. It has recently been shown that the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors leads to a reduction in CV outcomes in patients with type 2 diabetes mellitus (T2DM), including mortality and heart failure hospitaliza...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Upsala Medical Society
2019-01-01
|
Series: | Upsala Journal of Medical Sciences |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/03009734.2018.1515281 |